![Stephan Schann](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephan Schann
Technik-/Wissenschafts-/F&E-Leiter bei Domain Therapeutics SA
Profil
Stephan Schann is currently the Chief Scientific Officer at Domain Therapeutics SA since 2008.
He previously worked as a Team Leader at Evotec (UK) Ltd.
Dr. Schann obtained his graduate and doctorate degrees from the University of Strasbourg.
Aktive Positionen von Stephan Schann
Unternehmen | Position | Beginn |
---|---|---|
Domain Therapeutics SA
![]() Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2008 |
Ehemalige bekannte Positionen von Stephan Schann
Unternehmen | Position | Ende |
---|---|---|
Evotec (UK) Ltd.
![]() Evotec (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Evotec SE, Evotec (UK) Ltd. provides research and development on natural sciences and engineering. The company is based in Abingdon, UK and was founded in 1991. | Corporate Officer/Principal | - |
Ausbildung von Stephan Schann
University of Strasbourg | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Domain Therapeutics SA
![]() Domain Therapeutics SA BiotechnologyHealth Technology Domain Therapeutics SA discovers and develops drug candidates targeting G-protein coupled receptors (GPCR) in all major therapeutic fields. The firm?s products include technologies, such as DTect-All and BioSens-All. Its services encompass allosteric modulators identification, biased ligands selection, orphan and historically intractable GPCRs address and high throughput screening campaign. The company was founded by Maurice Isra?l, Pierre Potier, Bernard Jacques Alex Gilly, Yves Dunant and Pascal Neuville in 2008 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
Evotec (UK) Ltd.
![]() Evotec (UK) Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Evotec SE, Evotec (UK) Ltd. provides research and development on natural sciences and engineering. The company is based in Abingdon, UK and was founded in 1991. | Commercial Services |